Avadomide (Standard)

Avadomide (Standard) is the analytical standard of Avadomide. This product is intended for research and analytical applications. Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities[1][2][3].

Product Specifications

CAS Number

[1015474-32-4]

Product Name Alternative

CC 122 (Standard)

UNSPSC

12352005

Target

Apoptosis; E1/E2/E3 Enzyme; Molecular Glues; NF-κB; Reference Standards

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; NF-κB; Others; PROTAC

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(C(N1C(C)=NC2=C(C(N)=CC=C2)C1=O)CC3)NC3=O

Molecular Formula

C14H14N4O3

Molecular Weight

286.29

References & Citations

[1]Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an IFN response and has antitumor activity in DLBCL.Blood.Aug 6;126 (6) :779-89.|[2]Rasco DW, et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25 (1) :90-98.|[3]Nishi H, et al., Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2023 Oct;92 (4) :303-314.